PharmaCyte Biotech (PharmaCyte Biotech) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jan. 2024)

PharmaCyte Biotech Cash-to-Debt Chart

PharmaCyte Biotech Annual Data
	Trend	Apr14	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23
Cash-to-Debt		Get a 7-Day Free Trial					No Debt	11.93	No Debt	No Debt	No Debt

PharmaCyte Biotech Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of PharmaCyte Biotech's Cash-to-Debt

For the Biotechnology subindustry, PharmaCyte Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Cash-to-Debt falls into.

PharmaCyte Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PharmaCyte Biotech's Cash to Debt Ratio for the fiscal year that ended in Apr. 2023 is calculated as:

PharmaCyte Biotech had no debt ⁽¹⁾.

PharmaCyte Biotech's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

PharmaCyte Biotech had no debt ⁽¹⁾.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech  (NAS:PMCB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

PharmaCyte Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCyte Biotech (PharmaCyte Biotech) Business Description